Full-Time
Cloud-connected medical devices and software platforms
No salary listed
Austell, GA, USA
In Person
On-site role at the Lithia Springs distribution center (Atlanta area).
Bachelor's
See people who can refer or advise you
ResMed creates cloud-connected medical devices and software platforms to treat and manage sleep apnea, COPD, and other chronic diseases. Its devices (like sleep therapy gear) collect patient data and deliver therapy, while connected software platforms enable remote monitoring, coaching, and caregiver support. The company sells medical devices and offers software subscriptions, generating revenue from product sales and ongoing service fees. Unlike some competitors, ResMed combines hardware with cloud-based analytics and a broad ecosystem that supports patients, healthcare professionals, and caregivers across more than 120 countries. Its goal is to improve patient care and quality of life while reducing hospital visits and overall healthcare costs.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1989
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
Parental Leave
401(k) Retirement Plan
Employee Assistance Program (EAP)
Are Resmed CDI (ASX:RMD) shares good value in 2026? Want to value the Resmed CDI (ASX:RMD) share price? Here are 6 key metrics you need to consider. The Resmed CDI (ASX:RMD) share price is down -10.53% since the beginning of the year. So, how can you put a value on the RMD share price? RMD share price in focus. ResMed is a medical equipment company based in San Diego, California, but originally founded in Australia by Peter Farrell. The company provides cloud-connectable continuous positive airway pressure, or CPAP, machines for the treatment of obstructive sleep apnea (OSA). ResMed shares are listed both on the NYSE and the ASX. Because the primary listing is in the US, the market announcements and reports might look a bit different to other Australian companies as they follow the US format. ResMed is a global company with 10,000+ employees and a presence in over 140 countries. It has two primary business units: Sleep and Respiratory Care, and Software as a Service (SaaS). The industry-leading CPAP machines for sleep apnea are provided under the Sleep and Respiratory Care business. This covers patients ranging from those who only require therapy from CPAP systems at night to those who are dependent on non-invasive or invasive ventilation for life-support. Within the SaaS unit ResMed provides software used in durable or home medical equipment (DME/HME). Basically, it assists in out-of-hospital care. ResMed leverages its industry-leading hardware (e.g. masks and humidifiers) and its SaaS data to drive insights, improve outcomes and reduce overall healthcare costs. The key metrics. If you've ever tried reading a company's income statement on the annual report, you'll know just how complex it can get. While there are any number of ways you could slice up the statement, three key figures are revenue, gross margin, and profit. Revenue is important for obvious reasons - everything else (profit, margins, return on equity etc.) is downstream of a company's ability to generate sales and revenue. What The Rask Group is looking for is not so much the absolute number, but the trend. RMD last reported an annual revenue of $4,685m with a compound annual growth rate (CAGR) over the last 3 years of 13.6% per year. The next thing The Rask Group'll want to consider is the gross margin. The gross margin tells The Rask Group how profitable the core products/services are - before you take into account all the overhead costs, how much money does the company make from selling $100 worth of goods and services? RMD's latest reported gross margin was 57.4%. Finally, The Rask Group get to profit, the real headline number. Last financial year Resmed CDI reported a profit of $1,021m. That compares to 3 years ago when they made a profit of $475m, representing a CAGR of 29.1%. Financial health of RMD shares. Next, The Rask Group could consider the capital health of the company. What The Rask Group is trying to work out is whether the company is generating a reasonable return on their equity (the total shareholder value) and whether they have a good safety buffer. One important measure to consider is net debt. This is simply the total debt minus the company's cash holdings. In the case of RMD, the current net debt sits at -$624m. A high number here means that a company has a lot of debt which potentially means higher interest payments, greater instability, and higher sensitivity to interest rates. A negative value on the other hand indicates the company has more cash than debt, which can be seen as good (a big safety buffer) or bad (inefficient capital allocation). A metric that might be more valuable to The Rask Group is the debt/equity percentage. This tells The Rask Group how much debt the company has relative to shareholder ownership. In other words, how leveraged is the company? Resmed CDI has a debt/equity ratio of 18.0%, which means they have more equity than debt. Finally, The Rask Group can look at the return on equity (ROE). The ROE tells The Rask Group how much profit a company is generating as a percentage of its total equity - high numbers indicate the company is allocating capital efficiently and generating value, while a low number suggests that company growth may be starting to slow. RMD generated an ROE of 22.7% in FY24. What to make of RMD shares? As a growth company, one way to put a general prediction on the RMD share price could be to compare its price-to-sales multiple over time. Currently, Resmed CDI shares have a price-sales ratio of 4.74x, compared to its 5-year average of 8.70x, meaning its shares are trading below their historical average. This could mean that the share price has fallen, or sales have increased, or both. In the case of RMD, revenue has been growing over the last 3 years. Please keep in mind that context is important - and this is just one valuation technique. Investment decisions can't just be based on one metric. The Rask websites offer free online investing courses, created by analysts explaining things like Discounted Cash Flow (DCF) and Dividend Discount Models (DDM). They even include free valuation spreadsheets! Both of these models would be a better way to value the RMD share price. How rich are you? Over 5,694 Australian investors have already used the Rask Wealth Checker to know exactly where they stand. Analyse your Superannuation, property, shares or ETFs, crypto, your income - and more! - in seconds with its free wealth tool that has now checked assets totalling $16,790,107,141! It takes just 30 seconds and The Rask Group'll turn your finances into great visualisations to help you summarise how your net wealth or income breaks down. You can instantly access its free wealth tool by clicking here now. No gimmicks. No credit cards. No payment. The Rask Group'll analyse your net worth and email you the wealth summary. Rask Invest research team. The Rask Invest research team produces daily ASX news and research on ASX-listed companies and funds. Join the conversation inside the free investor community. Click here to have your say. Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don't know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read its Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #563 907. A $50,000 per year passive income special report Join more 50,000 Australian investors who read its weekly investing newsletter and The Rask Group'll send you its passive income investing report right now.
Resmed announces appointment of Carol Burt as Lead Director and planned retirement of Director Ron Taylor. August 17, 2026 16:10 ET | Source: Resmed, Inc. * Nominating and Governance Chair Carol Burt to become Lead Director. * Ron Taylor to retire after more than 21 years of service on Resmed's Board of Directors. SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) - Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lead Director on November 15, 2026. She will succeed Ron Taylor, Resmed's current Lead Director, who is not standing for reelection at the company's 2026 Annual Meeting of Stockholders on November 18, 2026, and will retire after more than 21 years of service to the company. The Board has appointed Carol Burt to serve as Lead Director, effective November 15, 2026. Burt has served on Resmed's Board since 2013 and currently chairs the Nominating and Governance Committee. She is also a member of the Audit Committee and the Compliance, Privacy and Quality Committee. Burt's extensive board leadership and governance experience position her well to serve as Lead Director as the company continues to execute its long-term strategy. "Carol is an outstanding leader with deep governance experience, broad healthcare industry knowledge and a strong commitment to Resmed's mission," said Mick Farrell, Resmed's Chairman and CEO. "I look forward to continuing to work closely with Carol and the entire Board as we advance our strategy and create long-term value for our shareholders." Ron Taylor joined Resmed's Board of Directors in 2005 and has served in numerous leadership roles, including as Lead Director since 2013. During his tenure, Ron helped guide the company's governance, strategy and long-term growth while providing thoughtful leadership and independent oversight during a period of significant growth and transformation. "Ron has made extraordinary contributions to Resmed over the past two decades," said Farrell. "His integrity, sound judgment and unwavering commitment to our patients, employees and shareholders have helped shape Resmed. On behalf of the Board and all Resmedians, I thank Ron for his outstanding service and wish him and his family all the very best." About Resmed Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more at Resmed.com and follow @Resmed. Company Profile Resmed, Inc. Industry: Medical Equipment Website: https://www.resmed.com/ Recommended reading.
ResMed reported 9% quarterly revenue growth to $1.5 billion and 16% non-GAAP earnings per share growth to $2.95 for its fourth quarter of fiscal 2026. Full-year revenue rose 10%, with free cash flow exceeding $1.6 billion. The company's sleep apnea business continues expanding. Data from 2.5 million patients shows those prescribed both GLP-1 drugs and PAP therapy are 11% more likely to begin treatment. A partnership with Oura has driven 13,000 users to sleep assessments, with three-quarters previously undiagnosed. However, life support device revenue fell 45% in the Americas after ResMed suspended new Astral ventilator sales. The company booked a $42 million provision and expects the pause to reduce fiscal 2027 revenue by roughly $75 million. Free cash flow dropped 21% to $404 million.
ResMed reported second-quarter revenue of $1.46 billion, meeting analyst estimates with 8.6% year-on-year growth. However, operating margin fell to 30.7% from 33.7% the previous year, pressuring shares. The margin decline stemmed from higher R&D and supply chain costs amid inflation. CEO Mick Farrell cited ongoing investments in innovation and efficiency as both necessary and challenging. The company also took a $42 million charge for a field safety action on its Astral devices, suspending future sales of that product line. During the earnings call, analysts probed margin pressures, acquisition strategy, and the impact of GLP-1 treatments on patient adoption. Management indicated focus on tuck-in acquisitions between $100 million and $500 million, particularly in digital health.
ResMed reported second-quarter revenue of $1.46 billion, meeting analyst expectations with 8.6% year-on-year growth. The medical device company's adjusted earnings per share of $2.95 beat estimates by 2%. Despite steady revenue growth, ResMed's operating margin declined to 30.7% from 33.7% in the prior year period. Management attributed the compression to higher R&D and supply chain costs amid inflation. The company also recorded a $42 million charge related to a field safety action on its Astral devices. Chief executive Mick Farrell highlighted ongoing investments in innovation and supply chain efficiency. Looking ahead, ResMed expects modest price increases and productivity initiatives to offset inflation in electronic components and freight whilst expanding its digital health ecosystem.